Traitement du SARS-CoV-2 en pédiatrie : quelles évidences et quelle utilité ? [Treatment of SARS-CoV-2 in paediatrics : what is the evidence to date?]

Détails

Ressource 1Télécharger: RMS_Traitement du SARS-CoV-2 en pédiatrie.pdf (1297.37 [Ko])
Etat: Public
Version: Final published version
Licence: CC BY-NC-ND 4.0
ID Serval
serval:BIB_9FD582ADE3EC
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Traitement du SARS-CoV-2 en pédiatrie : quelles évidences et quelle utilité ? [Treatment of SARS-CoV-2 in paediatrics : what is the evidence to date?]
Périodique
Revue medicale suisse
Auteur⸱e⸱s
Fougère Y., Rohr M., Vetter P., Wagner N.
ISSN
1660-9379 (Print)
ISSN-L
1660-9379
Statut éditorial
Publié
Date de publication
17/02/2021
Peer-reviewed
Oui
Volume
17
Numéro
726
Pages
344-348
Langue
français
Notes
Publication types: Journal Article
Publication Status: ppublish
Résumé
Although SARS-CoV-2 infects individuals of all ages, children show less severe symptoms. Nevertheless, the very rare COVID-19 severe cases in paediatrics require our full attention. Much research has been conducted and is still ongoing on effective treatments. On the antiviral front, no molecule has been proven effective yet and the results of several studies on the benefit of monoclonal antibodies and convalescent plasma are pending. On the side of immunomodulators, the benefit of steroids has been demonstrated for patients severely ill. Other molecules are being investigated. However, all these studies focused on adults and paediatric data are warranted.
Mots-clé
Adult, COVID-19/therapy, Child, Coronavirus Infections, Humans, Immunization, Passive, Pediatrics, SARS-CoV-2, COVID-19 Serotherapy
Pubmed
Création de la notice
01/03/2021 14:39
Dernière modification de la notice
05/12/2023 8:15
Données d'usage